Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year

“During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax and azacitidine for frontline treatment of newly diagnosed acute myeloid leukemia,” said William Rice, CEO. “Tuspetinib brings favorable safety and broad activity across AML genetic subtypes to the TUS+VEN+AZA triplet therapy, which already has achieved complete remissions in difficult-to-treat and underserved TP53-mutated/CK AML and FLT3-wildtype AML patients in our ongoing TUSCANY trial. We look forward to sharing more data as the trial evolves.”